Showing results (631-640 of 665) with videos related to

Sort By:
Pageof 67
Autoimmunity Reviews|July 6, 2026
The landscape of serum autoantibodies in lupus nephritisMaurizio Bruschi, Federico Alberici, Gabriella Moroni, et al.
European Urology Open Science|July 11, 2022
The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk CalculatorSneha Parekh, Parita Ratnani, Ugo Falagario, et al.
The New England Journal of Medicine|December 21, 2012
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritisNicolino Ruperto, Hermine I Brunner, Pierre Quartier, et al.
Rheumatology (Oxford, England)|October 5, 2017
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspectsLisa G Rider, Nicolino Ruperto, Angela Pistorio, et al.
Annals of the Rheumatic Diseases|August 2, 2012
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisGeorge K Bertsias, Maria Tektonidou, Zahir Amoura, et al.
Autoimmunity Reviews|March 29, 2024
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidenceMaurizio Bruschi, Andrea Angeletti, Marco Prunotto, et al.
Lancet (London, England)|November 12, 2021
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trialNicolino Ruperto, Hermine I Brunner, Olga Synoverska, et al.
Rheumatology (Oxford, England)|January 25, 2021
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritisNicolino Ruperto, Hermine I Brunner, César Pacheco-Tena, et al.
Annals of the Rheumatic Diseases|May 17, 2017
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trialHermine I Brunner, Nicolino Ruperto, Nikolay Tzaribachev, et al.
Annals of the Rheumatic Diseases|August 11, 2022
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an updateDaniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Pageof 67